MISSION VIEJO, CA, November 6, 2026 — DBM Aesthetics released updated guidance outlining how aesthetic providers should distinguish injectable skin boosters from Luchel Skin Booster, a professional topical product intended for application to intact skin. The guidance emphasizes product identification, intended use, treatment planning, documentation, and product-specific safety procedures.

The update addresses differences among products marketed under the skin booster category, including variations in ingredients, treatment depth, regulatory status, application methods, and intended outcomes. DBM Aesthetics developed the guidance to help U.S. medical spas and aesthetic providers separate injectable treatment protocols from topical professional skin care workflows.

The guidance outlines a structured product review process before treatment. Providers should confirm the exact product name, ingredients, intended use, treatment area, manufacturer instructions, packaging condition, expiration date, lot number, and applicable placement requirements before starting a procedure.

For injectable skin boosters, the guidance emphasizes patient assessment, medical history review, informed consent, standardized photography, treatment documentation, and product-specific technique. It also notes that no universal injection depth, dose, device, or placement pattern applies across all products marketed as skin boosters.

The operational framework includes documentation of the product used, lot number, treatment amount, device, placement plane, treatment sites, aftercare instructions, and procedures for responding to adverse events. Providers should also maintain clear escalation procedures for symptoms that may require urgent medical assessment.

The guidance separately identifies Luchel Skin Booster as a topical professional product rather than an injectable skin booster. Luchel is supplied as a two-component system: 160 mg of fully solubilized mPEG PDLLA and a 3 mL liquid base containing hyaluronic acid, polynucleotide, and proteoglycan. Mix the components before topical use.

DBM Aesthetics states that Luchel should be applied topically to intact skin according to its product instructions and should not be injected, implanted, used as a dermal filler, or introduced through microneedling channels unless applicable product and device labeling specifically permits that use.

Medical spas may incorporate Luchel into professional hydration services or other noninjectable skin care workflows. The guidance recommends that providers assess the skin for irritation, infection, open areas, or recent procedures before application and maintain appropriate storage, packaging inspection, lot tracking, and response documentation practices.

DBM Aesthetics said its product guidance will continue to focus on intended-use clarity, structured provider workflows, and separating topical product applications from injectable treatment protocols as professional skin care practices continue to evolve.

Media Contact

DBM Aesthetics
Phone: +1 949-329-8124
Email: daniel.lee@dbmcorpusa.com
Website: DBM Aesthetics

About DBM Aesthetics

DBM Aesthetics provides U.S. aesthetic providers with professional product information, intended-use guidance, and ordering support for Luchel Skin Booster. Luchel is positioned as a topical professional skin care product focused on surface hydration, softness, smoothness, and skin conditioning.

Contact Information:

DB Medical Corporation

23263 Madero Suite B
Mission Viejo, CA 92691
United States

Daniel Lee
(949) 329-8124
https://dbmcorpusa.com/